Lexicon pharmaceuticals, inc./de (LXRX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues:
Net product revenue

-

-

-

-

0

-

-

-

-

-

-

Collaborative agreements

289,231

36,271

75,621

79,101

129,728

22,593

2,109

783

1,632

4,191

9,334

Royalties and other revenue

511

355

178

155

286

261

113

306

217

717

1,366

Total revenues

322,073

63,209

91,689

79,256

130,014

22,854

2,222

1,089

1,849

4,908

10,700

Operating expenses:
Cost of sales (including finite-lived intangible asset amortization)

3,231

2,491

1,899

0

0

-

-

-

-

-

-

Research and development, including stock-based compensation of $2,176 and $1,768, respectively

91,924

100,243

152,223

163,973

95,187

89,279

89,682

82,574

91,828

78,520

81,238

Earnings Per Share, Diluted

1.16

-1.14

-1.17

-

-

-

-

-

-

-

-

Selling, general and administrative expenses, included stock-based compensation of $2,256 and $1,643, respectively

56,835

63,754

66,090

43,157

23,835

19,411

17,121

17,043

17,350

19,396

19,418

Increase in fair value of Symphony Icon, Inc. purchase liability

0

0

2,101

-703

5,927

1,428

-2,210

9,887

6,766

2,710

0

Impairment loss on buildings

-

-

-

-

3,597

13,102

0

-

-

-

-

Total operating expenses

180,628

166,488

222,313

206,427

128,546

123,220

104,593

109,504

115,944

100,626

100,656

Loss from operations

141,445

-103,279

-130,624

-127,171

1,468

-100,366

-102,371

-108,415

-114,095

-95,718

-89,956

Gain on investments, net

-

-

-

-

-

-

-

-

-

141

1,173

Interest income

-

-

-

-

-

-

-

213

255

519

880

Interest expense

20,676

20,777

6,984

6,567

6,722

2,253

1,971

2,114

2,528

2,719

2,966

Interest and other income, net

3,350

3,508

1,954

2,293

572

2,255

216

105

153

-4,024

-2,550

Net income (loss) before taxes

124,119

-120,548

-135,654

-131,445

-4,682

-100,364

-104,126

-

-

-101,801

-93,419

Income tax benefit

-6,000

0

-12,700

0

0

-

-

-

-

-

-

Income tax benefit

-

-

-

-

0

-70

0

-

-

-26

-102

Consolidated net loss

-

-

-

-

-

-

-

-

-

-

-93,317

Less: net loss attributable to Symphony Icon, Inc.

-

-

-

-

-

-

-

-

-

-

-10,537

Net loss

130,133

-120,548

-122,993

-131,445

-4,682

-100,294

-104,126

-110,211

-116,215

-101,775

-82,780

Net loss per common share, Basic and Diluted

1.23

-1.14

-1.17

-

-

-

-

-

-

-

-

Net loss per common share, basic and diluted

-

-

-

-1.27

-0.05

-1.31

-1.42

-0.23

-0.34

-0.34

-0.57

Other comprehensive loss:
Unrealized gain on investments

96

210

-27

24

-156

-65

-21

2

16

5

-

Comprehensive loss

130,229

-120,338

-123,020

-131,421

-4,838

-100,359

-104,147

-110,209

-116,199

-101,770

-

Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)

28,600

0

0

-

-

-

-

-

-

-

-

Weighted Average Number of Shares Outstanding, Diluted

116,747

105,830

105,237

103,863

103,591

76,347

73,302

489,707

340,761

302,844

145,465

Weighted Average Number of Shares Issued, Basic

106,218

105,830

105,237

-

-

-

-

-

-

-

-